Chemotherapy of the acquired immune deficiency syndrome (AIDS): Non-nucleoside inhibitors of the human immunodeficiency virus type 1 reverse transcriptase

Add time:08/28/2019    Source:sciencedirect.com

Several classes of non-nucleoside analogues (i.e. TIBO and HEPT derivatives) have been identified that specifically interact with the reverse transcriptase (RT) of human immunodefiency virus type 1 (HIV-1). These derivatives inhibit the replication of HIV-1 in various cell lines, including peripheral blood lymphocytes and monocytes/macrophages, at concentrations that are 10,000- to 100,000-fold lower that the cytotoxic concentrations. At the HIV-1 RT level, they appear to interact with a specific allosteric “TIBO” site, which may be functionally and also structurally associated with the substrate binding site. The TIBO and TIBO-like compounds are orally bioavailable. In vivo they sustain plasma drug levels that are well above the concentrations required to inhibit virus replication in vitro.

We also recommend Trading Suppliers and Manufacturers of 5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil (cas 132774-45-9). Pls Click Website Link as below: cas 132774-45-9 suppliers

Prev:Synthesis of 6-arylvinyl analogues of the HIV drugs SJ-3366 and Emivirine
Next:The design and synthesis of N-1-alkylated-5-aminoaryalkylsubstituted-6-methyluracils as potential non-nucleoside HIV-1 RT inhibitors)